Asianet Newsable on MSN
Compass Pathways clears another hurdle – builds stronger FDA case for its much-awaited depression therapy
Compass Pathways posted 26-week data from its trial evaluating COMP360, showing rapid and durable benefits, while maintaining ...
Vertex makes its largest-ever deal, skyrocketing health insurance costs, and more biotech news from The Readout ...
Among patients with stable CAD or PAD, those with diabetes appear to derive greater absolute benefits from a combination of low-dose rivaroxaban (Xarelto; Bayer/Janssen) and aspirin compared with ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results